Pet Cancer Therapeutics Market By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Combination Therapy), By Pet Type (Dog, Cat and Others), By Mode of Administration (Oral, Topical, Intravenous), By Application (Lymphoma, Mast Cell Cancer, Melanoma, Mammary and Squamous Cell Cancer and Others) and By Region - Trends, Analysis and Forecast till 2034

The market for pet cancer treatments is expected to rise due to rising research and development (R&D) costs associated with managing pet malignancies and rising incidence and prevalence rates for these diseases. A number of major players will also drive the market for pet cancer therapies throughout the forecast period, providing a wide range of cancer medications for the treatment of pet cancer.

For example, the U.S. Food and Drug Administration (FDA) approved Tanovea-CA1, or rabacfosadine, for injection, with conditional approval in January 2017 to treat canine lymphoma. Thanks to the conditional approval, Tanovea-CA1's maker, VetDC, Inc., a veterinary cancer treatment company, was able to lawfully offer his novel animal medication on the market before receiving permission. Additionally, VetDC made Tanovea-CA1 commercially available in the United States in April 2017 for the treatment of lymphoma in canines.